#97 – Peter Hotez, M.D., Ph.D.: COVID-19: transmissibility, vaccines, risk reduction, and treatment
“The next two weeks will be the critical period where we may start to see this reach a peak.” —Peter Hotez, M.D., Ph.D.
#104 – COVID-19 for kids with Olivia Attia
“The underlying theme to how we got here is we didn’t really do the things we needed to do before it was too late.” — Peter Attia
#111 – AMA #14: What lab tests can (and cannot) inform us about our overall objective of longevity
“Metabolic health really matters. It is the common thread that links all of these chronic diseases.” — Peter Attia
SARS-CoV-2 and the host response: psychological stress
I’ve been thinking a lot about the role of psychological stress and how it relates to our response to SARS-CoV-2, the virus that causes COVID-19.
COVID framework: How does this thing end?
I tried to explain to my 5-year-old son where we currently stand in this pandemic. His questions are the ones that truly matter right now.
#118 – Lloyd Klickstein, M.D., Ph.D.: Rapamycin, mTOR inhibition, and the biology of aging
“Our approach is to address serious aging-associated diseases, and if we’re successful, the side effect will be longevity.” — Lloyd Klickstein
#128 – Irene Davis, Ph.D.: Evolution of the foot, running injuries, and minimalist shoes
“Rather than have the runners adapt to the running, they took the shoe and adapted it to the runner.” — Irene Davis
#137 – Paul Offit, M.D.: An expert perspective on COVID-19 vaccines
“When people talk to me about how nervous they are that antibodies are fading, I’m not sure you should be nervous about it yet. Let’s wait to see what happens as we move forward with these vaccines.” — Paul Offit
Q&A on Alzheimer’s disease drug therapy with Dr. Richard Isaacson
Check out more content with neurologist, Richard Isaacson, M.D.: (Oct 1, 2018) #18 – Richard Isaacson, M.D.: Alzheimer’s prevention (Nov…